# Stanford



# Mona D. Shah, MD, MBA

Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology

#### **CLINICAL OFFICE (PRIMARY)**

• Pediatric Hematology and Oncology

725 Welch RdMC 5913Palo Alto, CA 94304

**Tel** (650) 497-8953 **Fax** (650) 497-8101

#### Bio

#### BIO

Dr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.

Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children's Hospital, Houston, TX.

Dr. Shah joined Genentech (a Member of the Roche Group)'s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.

After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.

Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!

Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family.

#### **CLINICAL FOCUS**

• Pediatric Hematology-Oncology

#### PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2009)
- Fellowship: Baylor College of Medicine-Pediatric Hematology/Oncology Fellowship (2007) TX
- Board Certification: Pediatrics, American Board of Pediatrics (2005)
- Residency: Rainbow Babies and Children's Hospital Pediatric Residency (2004) OH
- Medical Education: University of Maryland Baltimore (2001)

### **Publications**

## **PUBLICATIONS**

• Navigating your career path in pediatric hematology/oncology: On and off the beaten track. *Pediatric blood & cancer*Zweidler-McKay, P. A., Hogan, M. S., Jubran, R., Black, V., Casillas, J., Harper, J., Malempati, S., Margolin, J., Felgenhauer, J., Sakamoto, K. M., Franklin, J., Shah, M., Seibel, et al

2016; 63 (10): 1723-1730